Donnerstag, 25. April 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Evaluation of Nidus Occlusion After Gamma Knife Radiosurgery of Cerebral Arteriovenous Malformations Using Magnetic Resonance Imaging

Rekrutierend

NCT-Nummer:
NCT03995823

Studienbeginn:
Juli 2019

Letztes Update:
05.01.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Hemangioma, Intracranial Arteriovenous Malformations, Arteriovenous Malformations, Congenital Abnormalities

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
Medical University of Vienna

Collaborator:
Medical Scientific Fund of the Mayor of Vienna

Kontakt

Studienlocations
(1 von 1)

Department of Neurosurgery, Medical University of Vienna
1090 Vienna
AustriaRekrutierend» Google-Maps
Ansprechpartner:
Josa M Frischer, MD, PhD
Phone: 004314040045510
E-Mail: josa.frischer@meduniwien.ac.at

Dorian Hirschmann, MD
Phone: 00436505549670
E-Mail: dorian.hirschmann@meduniwien.ac.at
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

Background

Cerebral arteriovenous malformations consist of tangled blood vessels forming a so-called

nidus which connects arteries to veins without the interposition of a capillary bed. Due to

subsequent structural changes of draining veins within the nidus, patients are at risk of

cerebral hemorrhage. Bleedings of AVMs are associated with high morbidity and mortality.

Therefore, once a cerebral AVM is diagnosed, preventive treatment usually is aimed for. If

hemorrhage already occurred treatment is necessary because of a high chance of re-bleeding.

Cerebral AVMs are likely to cause neurological symptoms such as seizures and focal deficits

without bleeding. These symptoms are usually due to the AVM's mass effect however, they have

also been discussed to be caused by a vascular steal syndrome.

Etiology

The etiology of cerebral AVMs is not known. Aside from the possibility of a multifactorial

cause it seems that genetic mutation and angiogenetic stimulation could play a role in their

development. It is also discussed whether AVMs develop in utero or through an angiopathic

reaction following ischemia or hemorrhage.

Epidemiology

The prevalence and incidence of cerebral AVMs are about 10 per 100,000 and 1 per 100,000;

respectively without sex predilection. The annual risk of intracranial hemorrhage ranges from

1.2% in unruptured AVMs to 4.8% when hemorrhage already occurred before. The mortality rate

among AVM patients after intracranial hemorrhage is 10-15%. The morbidity varies from 30-50%.

Of all AVM patients without hemorrhage about 15-40% suffer from seizures. Progressive

neurological deficit occurs at 6-12%.

Diagnosis

Cerebral AVMs are usually diagnosed by an MRI examination. They can easily be identified on

enhanced images but may also be visible without contrast due to edema or mass effect. The

current gold standard of diagnosis and evaluation of treatment success of cerebral AVMs is

digital subtraction angiography (DSA). This method uses injection of a contrast agent into

the patient's arteries and X-rays to visualize cerebral vessels. Imaging of the blood flow

over time and therefore accurate distinction of feeding and draining vessels within the nidus

is the major advantage of DSA. Subtraction of bones and soft tissue enables an optimal view

of the vascular system.

DSA has to be carried out as an inpatient procedure because of its invasiveness. Occurrence

of hematoma or pseudoaneurysm at the site of puncture and endovascular injury with

consecutive embolism are rare but possible complications. Further disadvantages of DSA are a

substantial exposure to radiation and the necessity of 24 hours of bed rest after the

procedure which may lead to an increased risk of thrombosis.

Classification - The Spetzler-Martin grading-system

Evaluation of the Spetzler-Martin grade (SM grade) requires three characteristics of the AVM.

first it is the size of the malformation regrouped into three categories. Next, the drainage

is of importance: one can differentiate between superficial only and deep veins partaking in

drainage. Finally, the eloquence of the brain tissue surrounding the lesion is considered.

Areas responsible for higher functions such as movement and sensibility, vision and language

are called eloquent. The thalamus, hypothalamus, brainstem and cerebellar peduncles are

eloquent regions. On the cerebral cortex sensorimotor areas and those responsible for

language and primary vision are eloquent.

The Spetzler-Martin system was developed to estimate the prognosis before surgical

intervention, but is also used for other treatment methods. The SM grade correlates well with

the difficulty of surgery and its outcome.

Treatment

There are different treatment options for cerebral AVMs: Microsurgical resection,

endovascular embolization and Gamma Knife radiosurgery, or combinations thereof. Independent

of AVM specifications and treatment option, any therapy bears the risk of cerebral hemorrhage

and ischemia and therefore permanent neurological deficit and death. Hence, the decision if

and how an AVM should be treated has to be made carefully with the intention to offer a

result better than the natural course of the disease. In order to answer the question if a

wait-and-see strategy is a valid option, a prospective, non-blinded, randomized, multicenter

study was conducted in 2014. The study compared the risk of death and stroke as well as

functional outcome between treated and untreated AVM patients.

The so-called ARUBA trial was interrupted six years after the beginning of randomization due

to an apparent superiority of the untreated group. The authors concluded that unruptured

cerebral AVMs should be managed conservatively.The study was harshly criticized by many

experts due to its setting and the interpretation of the data. One major limitation is that

different treatment options were not evaluated separately but as one interventional group.

Other limitations of ARUBA are a low number of cases - only 116 patients were randomized for

intervention and of those only five underwent microsurgical resection - and a short follow-up

of 33 months. At least, ARUBA shows the controversy existing among experts concerning

cerebral AVM treatment. The established treatment options will be explained below.

Microsurgical Resection

As microsurgical resection eliminates the risk of bleeding immediately, it still represents

the therapy of choice for most of the cerebral AVMs reaching a Spetzler-Martin score of one

to three. In order to expose a cerebral AVM, a bone flap of the patient's skull is raised and

the dura opened. Feeders are identified, coagulated and cut so the AVM can be resected in

total. Outcome of patients with an unruptured AVM undergoing microsurgery depends on their

Spetzler-Martin (SM) grade. According to a prospective cohort study from 2014 a permanent

neurological deficit is postoperatively seen in 1.6% of patients with SM scores 1 and 2. In

patient with SM grade 3 the risk of permanent neurological deficit after surgery rises to

14.0% and to 38.6% in patients with SM grades 4 and 5.

Endovascular Embolization

Endovascular embolization of an AVM is performed via the arterial route after puncture of a

peripheral artery. The AVM nidus is occluded by injection of an embolic material which clogs

its feeding arteries. According to a systematic review including more than 1,000 AVM patients

who had undergone endovascular embolization, this therapy lead to nidus occlusion in an

average of 13%, with a wide range from 0 to 94%. Permanent neurological deficit after

embolization was averagely seen in 6.6%, ranging from 0 to 28%. The endovascular approach is

often used to close small AVMs or to make larger AVMs amenable for radiosurgery or

microsurgery.

Gamma Knife Radiosurgery

Gamma Knife Radiosurgery can be performed either as a single therapy or in combination with

other treatment methods, most commonly combined with endovascular embolization. At the

Department of Neurosurgery, MUV radiosurgery of cerebral AVMs is performed with Gamma Knife

Perfexion® which uses 192 cobalt 60 sources to apply high dose radiation into an exactly

defined volume within the cranium. Gamma Knife radiosurgery is generally performed in local

anesthesia thus enabling the fixation of the stereotactic frame to the skull. In children

below 14 years of age Gamma Knife radiosurgery is performed under general anesthesia. Whereas

endovascular and surgical treatment immediately eliminate the risk of bleeding if carried out

successfully, nidus occlusion after Gamma Knife radiosurgery usually takes about two years.

During this time the bleeding risk is reported to be the same as in untreated patients. The

major advantage of radiosurgery is its non-invasiveness. Rates of complete nidus occlusion

after Gamma Knife radiosurgery of cerebral AVMs are reported to be about 85% for AVMs with a

SM grade 1 to 3. A much lower rate of 54% for AVMs with a SM grade 4 and a rate of 0% for

AVMs with SM grade 5 show the dependence of the Spetzler-Martin grade. However, even if nidus

occlusion is not achieved in many AVMs with higher SM grade, a reduction of their size may

enable further treatment. Permanent neurological deficit after radiosurgery was seen in 5.1%

with a range from 0 to 21%.23 Complications of radiosurgery are adverse radiation effects

(ARE) which occur many years after intervention and include perilesional edema and cyst

formation. Those have to be differentiated from radiation induced changes (RIC) arising in

the first 1-2 years after treatment and including focal necrosis, white matter injury,

microangiopathy, sinus inflammation and atrophy.

Treatment Evaluation

The gold standard for the evaluation after AVM therapy is the catheter angiography; digital

subtraction angiography (DSA). As already mentioned in chapter Diagnosis, DSA has several

disadvantages like invasiveness, necessity of inpatient treatment and peri-interventional

risks. So far, MRI/MRA is a regularly performed evaluation method after Gamma Knife treatment

of AVMs but it still remains unclear if its accuracy is sufficient compared to that of DSA.

Numerous MRI protocols for imaging of cerebral vascular pathologies exist. According to a

small prospective study a specific MRI protocol focusing on blood flow characteristics called

arterial spin labeling (ASL) was superior to conventional contrast enhanced MRI in the

evaluation of AVM nidus occlusion after stereotactic radiosurgery. Using DSA as a reference,

seven out of seven patients with complete nidus occlusion where assessed correctly by ASL

imaging, so were three patients with a persisting AVM nidus.

However, in those three cases, according to the contrast enhanced MRI the nidus was falsely

rated as occluded. A retrospective study comparing conventional MRI/MRA to DSA found 80%

sensitivity and 90% specificity of standard MRI/MRA for detection of AVM nidus occlusion

after stereotactic radiosurgery in a series of 136 patients.

Objectives and hypotheses

Objective:

To evaluate sensitivity and specificity of a standardized MRI/MRA protocol compared to that

of DSA for detection of nidus occlusion after Gamma Knife radiosurgery of cerebral AVMs

Hypotheses:

H0: There is significant difference in sensitivity and specificity between MRI/MRA and DSA

for detection of nidus occlusion after Gamma Knife radiosurgery of cerebral AVMs.

H1: There is no significant difference in sensitivity and specificity between MRI/MRA and DSA

for detection of nidus occlusion after Gamma Knife radiosurgery of cerebral AVMs.

Methods

In this preliminary study the investigators plan to include about 50 radiosurgically treated

patients with cerebral AVMs. Patients participating in the study will not be exposed to any

additional risk compared to patients not participating in the study. Participants will

undergo a standardized MRI protocol at the Department of Radiology, MUV two years after Gamma

Knife treatment. The standardized MRI protocol replaces the follow-up-MRI two years after

treatment that is usually performed in private practice and often does not include all

required sequences. The standardized MRI protocol includes specific sequences allowing

analyzation of vascular pathologies. Those are a contrast enhanced three-dimensional MRA (T1

GE 3D +/- KM), a time-of-flight magnetic resonance angiography (TOF-MRA), arterial spin

labeling (ASL) and time resolved MRA with interleaved stochastic trajectories (TWIST-MRA).

Three dimensional MRA and TOF-MRA produce conventional images of vascular structures. ASL

enables more detailed imaging of the cerebral blood flow. TWIST-MRA produces time resolved

images. Hence, the major advantage of DSA should be reproduced with this method.

For evaluation of the parenchyma adjacent to the AVM, DWI and SWI sequences will allow

detection of ischemic areas and hemorrhage. Standard sequences (T2 sagittal, axial and

coronal) will also be produced. Participants of this study will be enrolled at the Gamma

Knife outpatient clinic of the Department of Neurosurgery, MUV. Nidus occlusion will be

evaluated by a neuroradiologist and compared to the gold standard of DSA performed at the

Department of Neurosurgery, MUV. Since the angiography (DSA) is the current gold standard in

AVM evaluation it will be performed in any case and is thus rated as outside of this study

protocol. Thus, sensitivity and specificity of MRI/MRA for detection of AVM nidus occlusion

will be assessed in comparison to the gold standard. Due to the fact that every case of

cerebral AVM treated by stereotactic radiosurgery at the Department of Neurosurgery, Medical

University of Vienna is assessed by MRI and DSA examinations after treatment, the

post-radiosurgical procedures of diagnosis do not pose any additional effort or risk for

patients participating in the study. In fact, patients may benefit from participation as they

do not need to care for scheduling of their MRI examination in private practice.

Statistical analysis

Due to an uneven distribution of data, statistical analysis will be performed with

nonparametric tests. Descriptive analysis of characteristics of patients and AVMs as well as

Gamma Knife parameters includes the median value and range as well as frequencies, numbers

and percentages. Statistical calculations for comparison between eventual treatment groups

include the Kruskal-Wallis, Mann-Whitney-U and Chi-square test for independent samples. To

support the hypothesis, the result of the MRI examination must be in accordance with the

result of the DSA examination in a vast majority of cases. The investigators set a 95%

threshold for the sensitivity of MRI examinations to be sufficient for confirming the

hypothesis in this preliminary setting. Relevant findings have to be confirmed in a larger

(multicenter) prospective study.

Sample size

The approximate sample size of 50 patients is due to the planned study duration of 3 years.

The study serves as a preliminary study and results may be confirmed by a larger

(multicenter) study.

Recruiting of patients

Patients will be recruited in the Gamma Knife outpatient clinic of the Department of

Neurosurgery, MUV. Patients must undergo or have undergone Gamma Knife radiosurgery due to

cerebral AVM. For inclusion patients must have their two-year follow-up MRI exam within the

duration of study. All patients have to sign a form for participation in the study after

purpose and process of the study has been explained to them. The investigators plan to enroll

about 50 patients for this study.

Quality and protection of data

Entry and handling of patient data will only be executed by trained medical staff involved in

the planning and conduction of the study. Patient data will be entered anonymized in a SPSS

file using IBM SPSS Statistics for Windows (Version 25.0 Armonk, NY: IBM Corp.).

Variables used in the registry

Patient sex: male/female Source: EDP system

Patient age: years Source: EDP system

AVM diameter: cm Source: pre-radiosurgical MRI

AVM localization: frontal, parietal, occipital, temporal, insular, limbic, cerebellar, brain

stem, basal ganglia, thalamus, intraventricular, corpus callosum Source: pre-radiosurgical

MRI

Number of AVM feeders: Number Source: pre-radiosurgical DSA

AVM-haemorrhage: Yes/No Source: Anamnesis in EDP system

RBAS (Modified Radiosurgery Based AVM score): <1 to >2 Source: Pre-radiosurgical MRI

VRAS (Virginia Radiosurgery AVM Scale): 0 to 4 points

Treatment: Radiosurgery only, Radiosurgery+Endovascular embolization, other combinations

including Radiosurgery Source: EDP system

Date of treatment: Date Source: EDP system

Gamma Knife parameters: Isodose (%), Marginal dose (Gy), Maximum dose (Gy), Radiation volume

(ccm) Source: EDP system

Substance for embolization in case of additional endovascular treatment to radiosurgery:

Histoacryl, Onyx, ethanol, coils, cyanoacrylate, Glubran

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Patients must undergo or have undergone Gamma Knife radiosurgery due to cerebral AVM

- For inclusion patients must have their two-year follow-up MRI exam within the duration

of study

- All patients have to sign a form for participation in the study after purpose and

process of the study has been explained to them.

- For patients younger than 18 years, a parent or legal guardian has to sign a form for

participation after being informed about purpose and process of the study have been

explained to them.

Exclusion Criteria:

- Patients who do not give informed consent to participate

- Patients younger than 16 years

Studien-Rationale

Primary outcome:

1. Post radiosurgical AVM nidus obliteration on MRI (Time Frame - The MRI examination will be performed 2 years after Gamma Knife treatment.):
Sensitivity and specificity of MRI/MRA evaluated by catheter angiography

2. Post radiosurgical AVM nidus obliteration on DSA (Time Frame - DSA will be performed within 2 months after MRI/MRA):
Reference method for evaluation of sensitivity and specificity of MRI/MRA

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Evaluation of Nidus Occlusion After Gamma Knife Radiosurgery of Cerebral Arteriovenous Malformations Using Magnetic Resonance Imaging"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.